MET and neoplasm: After 5‐day treatment, Tepotinib strongly reduced tumour growth in cMet‐positive xenografts compared to a vehicle control, whereas no significant differences in growth were observed in tumours without cMet amplification between drug and vehicle group (Fig 5B).